DTC Limits May Land In Court After Opponents Fail To Strip FDA Powers From Bill
Executive Summary
The restrictions on direct-to-consumer advertising placed in the legislation to renew the prescription drug user fee program appear headed towards a showdown in the judicial branch after an attempt to remove them failed in a Senate committee
You may also be interested in...
GSK Avodart TV Ad Cited By FDA For Out-Of-This World Efficacy Comparison
FDA's letter to GlaxoSmithKline about a planetarium-themed TV spot for Avodart demonstrates several of the reasons that direct-to-consumer advertising remains in a troubled orbit above the pharmaceutical industry
GSK Avodart TV Ad Cited By FDA For Out-Of-This World Efficacy Comparison
FDA's letter to GlaxoSmithKline about a planetarium-themed TV spot for Avodart demonstrates several of the reasons that direct-to-consumer advertising remains in a troubled orbit above the pharmaceutical industry
Rx Safety Triggers Tighten As Senate Continues Work On FDA Revitalization Act
Provisions that specify which information will trigger the requirement for a drug to have a Risk Evaluation and Mitigation Strategy have been added to the FDA Revitalization Act as Senate floor debate on the bill continues